Innate Pharma (IPH) Stifel 2025 Virtual Targeted Oncology Forum summary

Strategic focus and pipeline overview

• Strategy centers on three pillars: ANKET platform, antibody-drug conjugates (ADCs), and late-stage assets.

• Eight clinical products span proprietary and partnered programs, covering early to late-stage development.

ANKET platform developments

• ANKET platform targets NKp46 and CD16 on natural killer cells, producing tri- and tetra-specific antibodies with superior efficacy and manageable safety.

• IPH6101 (partnered with Sanofi) showed a 33% complete response rate in refractory AML and is advancing to phase II and combination studies.

• IPH6401, initially for myeloma, is pivoting to inflammation and autoimmunity based on robust safety data.

• Proprietary IPH6501 targets CD20 with a tetra-specific design and is in phase I; preliminary safety and efficacy data expected late 2024 or early 2025.

• Plans to explore IPH6501 in autoimmune indications if safety profile remains favorable.

ADC portfolio progress

• ADC pipeline includes IPH4502 (Nectin-4 target), IPH43 (MICA/B target), and additional research-stage ADCs.

• IPH4502 targets a unique Nectin-4 epitope, showing activity in both high and low/moderate expressing tumors, expanding potential indications.

• Utilizes an exatecan payload, enabling efficacy in PADCEV-resistant tumors and supporting a fast-track, accelerated development path.

• IND cleared in September 2023; phase I initiated January 2024 with rapid cohort progression and preliminary data expected by year-end.

• Differentiation stems from antibody design, hydrophilic linker, and payload, offering advantages over existing ADCs.